Functional characterisation of cis-regulatory elements governing dynamic Eomes expression in the early mouse embryo

Claire S. Simon¹, Damien J. Downes², Matthew E. Gosden², Jelena Telenius², Douglas R. Higgs², Jim R. Hughes², Ita Costello¹, Elizabeth K. Bikoff¹, and Elizabeth J. Robertson¹

Author Affiliations:
1. The Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom
2. MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom

Corresponding Author: Elizabeth Robertson
Email: elizabeth.robertson@path.ox.ac.uk

Key Words:
Eomesodermin, enhancer, Capture-C, Nodal signaling, definitive endoderm

Summary Statement
Targeted genetic deletion and chromatin-conformation capture based characterisation of cis-regulatory elements governing dynamic Eomes expression identify an important endoderm enhancer required during mouse development.
Abstract

The T-box transcription factor (TF) Eomes is a key regulator of cell fate decisions during early mouse development. The cis-acting regulatory elements that direct expression in the anterior visceral endoderm (AVE), primitive streak (PS) and definitive endoderm (DE) have yet to be defined. Here, we identified three gene-proximal enhancer-like sequences (PSE_a, PSE_b and VPE) that faithfully activate tissue specific expression in transgenic embryos. However, targeted deletion experiments demonstrate that PSE_a and PSE_b are dispensable and only the VPE is required for optimal Eomes expression in vivo. Embryos lacking this enhancer display variably penetrant defects in anterior-posterior axis orientation and DE formation. Chromosome conformation capture experiments reveal VPE-promoter interactions embryonic stem cells (ESC), prior to gene activation. The locus resides in a large (500kb) pre-formed compartment in ESC and activation during DE differentiation occurs in the absence of 3D structural changes. ATAC-seq analysis reveals that VPE, PSE_a, and four additional putative enhancers display increased chromatin accessibility in DE associated with Smad2/3 binding coincident with transcriptional activation. In contrast, activation of the Eomes target genes Foxa2 and Lhx1 is associated with higher order chromatin reorganisation. Thus diverse regulatory mechanisms govern activation of lineage specifying TFs during early development.
Introduction

Reciprocal signaling cues between the pluripotent epiblast and adjacent tissues, namely the extra-embryonic ectoderm (ExE) and visceral endoderm (VE), precisely co-ordinate cell fate decisions during gastrulation. Nodal/Smad signals from the epiblast are required for specification of the AVE, a discrete signaling center that establishes anterior-posterior (A-P) polarity (Brennan et al., 2001; Robertson, 2014; Stower and Srinivas, 2014). The A-P axis initially becomes visible at gastrulation, when proximal posterior cells undergo an epithelial-to-mesenchymal transition (EMT) at the PS to form nascent mesoderm. Slightly later, following distal extension of the streak, endoderm progenitors delaminate and emerge onto the surface of the embryo (Kwon et al., 2008).

The T-box transcription factor (TF) Eomesodermin (Eomes), acting downstream of Nodal/Smad signals, is required to promote AVE formation and orientation of the A-P axis (Arnold et al., 2008a; Ciruna and Rossant, 1999; Nowotschin et al., 2013), as well as EMT of nascent mesoderm cells (Arnold et al., 2008a; Costello et al., 2011; Russ et al., 2000; van den Ameele et al., 2012). At post-implantation stages Eomes is expressed in the ExE and embryonic-VE, robustly induced at the onset of gastrulation in the PS, maintained in the anterior PS as it extends, before being abruptly lost coincident with node formation (Kwon and Hadjantonakis, 2007). Fate mapping experiments demonstrate that transient Eomes expression marks progenitors of the cardiovascular lineage, definitive endoderm (DE), node and midline (Costello et al., 2011).

Transgenic and targeted deletion approaches have provided insight into cell type specific developmental enhancers governing expression of key genes responsible for partitioning the pluripotent epiblast into discrete cell lineages. Proximal cis-regulatory regions within 20kb of the transcriptional start sites (TSS) directing spatiotemporally restricted expression of Nodal, Mesp1/2 and Lhx1 have been identified. Both the ASE, an intronic autoregulatory enhancer (Adachi et al., 1999; Norris and Robertson, 1999), and the Wnt signaling responsive 5’ PEE (Ben-Haim et al., 2006) cooperatively regulate Nodal expression. Mutant embryos lacking these genomic sequences display dose-dependent defects in specification of mesoderm and DE/midline progenitors (Norris et al., 2002; Vincent et al., 2003). Similarly, the Mesp1/2 genes, essential for formation of nascent mesoderm, are jointly regulated by the EME, an Eomes dependent enhancer (Costello et al., 2011; Haraguchi et al., 2001). Our recent work
demonstrates that *Lhx1*, required for AVE and anterior mesendoderm specification (Barnes et al., 1994; Shawlot and Behringer, 1995), is directly controlled by Eomes binding to a proximal promoter element (Nowotschin et al., 2013).

*Eomes*, rapidly induced in the proximal-posterior epiblast coincident with the acquisition of A-P polarity (Ciruna and Rossant, 1999), is widely viewed as a master regulator of mesendodermal lineages (Costello et al., 2011; Izumi et al., 2007; Teo et al., 2011; van den Ameele et al., 2012). Thus, *Eomes* represents the earliest lineage-specifying gene in the embryo-proper. However, relatively little is known about the *cis*-acting regulatory elements controlling its dynamic pattern of expression. Recent studies of mouse and human ESC have identified a conserved switch enhancer -7kb upstream of the TSS (Beyer et al., 2013; Kartikasari et al., 2013; Rada-Iglesias et al., 2011) that is repressed under self-renewing conditions (Teo et al., 2011), and becomes activated during mesoderm and endoderm differentiation. However, possible functional contributions made by this genomic region have yet to be assessed *in vivo*.

Here, we investigate the structural features of the locus that govern *Eomes* expression during early mouse development. Gain of function transgenic reporter assays identified three gene-proximal *Eomes* enhancer-like sequences (PSE_a, PSE_b and VPE). However, when we engineered germline deletions to evaluate their functional contributions *in vivo*, surprisingly, only the VPE was found to influence expression in the early embryo. We also exploited Next Generation (NG) Capture-C technology (Davies et al., 2016) to describe the 3D structural features of the locus. The *Eomes* promoter occupies a discrete 500kb regulatory compartment in ESC, and this chromatin conformation is not appreciably altered during DE differentiation. However, our ATAC-seq analysis revealed that the VPE, PSE_a and four additional distal regulatory elements located within this pre-formed compartment display increased chromatin accessibility and acquire Smad2/3 occupancy during DE differentiation. This mode of 3D genome organisation probably serves to facilitate rapid Nodal/Smad-dependent activation of the locus. In contrast, developmentally regulated *Foxa2* and *Lhx1* promoter-promoter and promoter-enhancer interactions seem to require substantial structural changes during the shift from transcriptionally inactive to active conformation.
Results

Identification of proximal *Eomes* enhancers active during gastrulation

Putative enhancer elements containing DNase hypersensitive sites and marked by H3K4me1, are considered to be active if also enriched for H3K27ac, or alternatively viewed as poised if enriched for H3K27me3 (Rada-Iglesias et al., 2011; Zentner et al., 2011). To identify candidate enhancers at the *Eomes* locus we examined ChIP-seq datasets from undifferentiated ESC, epiblast like cells (EpiLC) and mesodermal precursors (MES) (Alexander et al., 2015; Buecker et al., 2014; Consortium, 2012), corresponding to the E4.5 epiblast (ESC), the E5.5 epiblast (EpiLC) or E6.5 primitive streak (MES) cell populations.

We identified three DNase hypersensitive sites close to the *Eomes* promoter marked by H3K4me1 that show increased H3K27ac upon differentiation, including two sites (PSE_a and PSE_b) located close together, spanning a 5kb region between -11kb to -6kb upstream of the transcriptional start site (TSS), and a third candidate region (VPE) lying +8kb downstream of the TSS (Fig. 1A, Fig. S1A). Notably, the upstream cluster contains the previously described switch enhancer (PSE_b) activated during ESC differentiation to DE and mesendoderm (Beyer et al., 2013; Kartikasari et al., 2013). Additionally, two downstream DNaseI hypersensitive sites bound by CCCTC-binding factor (CTCF) were identified in ESC (Fig. S1A). The three proximal regions are highly conserved amongst mammals (Fig. S1A) and associated with H3K4me1/H3K27me3 in ESC, and thus probably represent poised enhancers, primed for activation. Consistent with a shift to the active state during the transition from pluripotency to lineage commitment, these regions contain increased H3K27ac and decreased H3K27me3 in EpiLC and MES. The homologous regions are also associated with active enhancer marks in human DE cultures (Fig. S1B).

To test activities of these candidate enhancers we generated transgenic strains carrying LacZ reporter constructs and subsequently examined embryonic expression at early post-implantation stages (Kothary et al., 1989). The 5kb upstream region was designated the PSE (**P**rimitive **S**treak **E**nhancer) because PSE-LacZ activity is restricted to the PS at early (ES), mid (MS) and late-streak (LS) stages (Fig. 1B). There was no detectable LacZ expression in the ExE or VE. On the other hand, the 0.7kb downstream enhancer designated the VPE (**V**isceral **e**ndoderm and **P**rimitive streak **E**nhancer), showed activity in the proximal-
posterior epiblast, and also in the AVE at pre-streak (PrS) stages (Fig. 1C). Slightly later, LacZ staining was detectable in the PS, nascent mesendoderm and the AVE, subsequently became restricted to the anterior PS, and was lost by LS stages. Collectively these three enhancers faithfully recapitulate the endogenous Eomes expression patterns within both the VE and embryo proper.

The PSE is dispensable for normal embryonic development

The 5kb PSE contains both an upstream element, PSE_a, as well as the previously described PSE_b switch enhancer reported to interact with the Eomes promoter during DE differentiation (Fig. S1A) (Beyer et al., 2013; Kartikasari et al., 2013). To investigate their functional activities in the context of the developing embryo we generated discrete germline targeted deletions (Fig. 2A, Fig. S2). Surprisingly, homozygous mice lacking the 2kb PSE_b genomic fragment ~8kb – ~6kb upstream of the TSS (ΔPSE_b) were recovered at Mendelian ratios and are indistinguishable from wild type littermates (Fig. 2B). These results demonstrate that the PSE_b is dispensable in vivo. It is well known that heterozygous mice carrying null alleles (Eomes<sup>GFP/+</sup>, Eomes<sup>LacZ/+</sup> or Eomes<sup>Δexon2-5/+</sup>) are fully viable (Arnold et al., 2008a; Arnold et al., 2009; Russ et al., 2000). To investigate whether the PSE_b deletion may compromise transcriptional output, we crossed Eomes<sup>ΔPSE_b/ΔPSE_b</sup> mice to those carrying the Eomes<sup>GFP/+</sup> allele (hereafter referred to as Eomes null; Eomes<sup>+/−</sup>). The resulting Eomes<sup>ΔPSE_b/−</sup> compound mutants develop normally (Fig 2C).

Next, we engineered a deletion that eliminates the entire 5kb PSE cluster (referred to as ΔPSE, Fig. S3). However, as for the PSE_b, removal of the entire PSE region in Eomes<sup>ΔPSE/ΔPSE</sup> mice has no noticeable effect on viability (Fig. 2B). Finally, crossing these deletion mutants with mice carrying the Eomes null allele also failed to perturb embryonic development (Fig. 2C). Thus, it appears that the PSE can activate expression in gain of function transgenic embryos. Nonetheless, this genomic region is clearly dispensable for Eomes expression in vivo.
Targeted deletion of the VPE leads to defective gastrulation

To investigate functional contributions made by the VPE we generated a targeted deletion lacking this 0.7kb region (Fig. S4). Homozygous ΔVPE mutants are viable and fertile (Fig. 2B). However, when we crossed EomesΔVPE/ΔVPE mice with EomesΔ/+ heterozygous animals carrying the null allele, we observed a significant under-representation of viable EomesΔVPE/- compound heterozygotes (Fig. 2C), with approximately 40% (n=18) of the expected numbers recovered at weaning (equivalent to EomesΔVPE/+, n=44). These results strongly suggest that EomesΔVPE acts as a hypomorphic allele.

Next, to determine the onset of lethality we examined embryos from E6.5 onwards. Approximately one third of EomesΔVPE/- embryos are morphologically normal. However, two distinct classes of abnormal embryos were recovered at roughly equivalent numbers. The most severely affected (Class I) mutants arrest at early gastrulation stages while a second group (Class II) progress to mid gestation (Fig. 2D).

In Class I embryos the AVE marker Hex is induced at E6.5 but remains localised to the distal tip. Thus, the AVE is specified but fails to migrate towards the prospective anterior side of the embryo. These embryos fail to correctly orient the A-P axis, and lack a discrete PS. At E7.5 mesoderm (Brachyury) and DE (Foxa2) markers are restricted proximally. Class I mutant embryos, distinguished by the accumulation of disorganised mesenchymal cells in the epiblast cavity and a constriction at the embryonic and extra-embryonic boundary, phenocopy those selectively lacking Eomes activity in the VE (Nowotschin et al., 2013). Taken together with results above that demonstrate VPE-LacZ expression in the VE, the simplest explanation is that these abnormalities are caused by loss of Eomes function in the VE.

The Class II embryos, representing approximately a third of the EomesΔVPE/- embryos, successfully establish normal A-P polarity. However, as gastrulation proceeds they display focal defects in the anterior PS (APS) and its derivatives the DE, midline, node and notochord. Brachyury expression in the PS fails to extend to the distal tip of the streak at E7.5. Foxa2 positive DE progenitors are specified but fail to migrate anteriorly. As judged by Afp expression, the VE is retained over the epiblast and fails to become distally restricted. These tissue disturbances probably reflect Eomes functional loss within the APS (Arnold et
al., 2008a; Teo et al., 2011). APS derivatives are known to provide essential trophic signals required for patterning the anterior neurectoderm (Arkell and Tam, 2012). Consistent with this, at E9.5 class II mutant embryos display ventral closure and neural tube defects, fused or malformed somites, and loss of forebrain tissue.

**The VPE is required for optimal *Eomes* expression levels**

To directly test whether targeted loss of the VPE compromises *Eomes* transcriptional output, we eliminated the VPE in the context of our *Eomes*\(^{\text{GFP}}\) reporter allele containing an EGFP-pA cassette inserted in-frame at the translational start site in exon 1 (Fig. 3A, Fig. S5) (Arnold et al., 2009) and performed flow cytometry analysis to quantify expression levels. The *Eomes*\(^{\text{GFP}}\) reporter is robustly activated during ESC differentiation to embryoid bodies (EBs) (Costello et al., 2011) (Fig. 3B). As shown in Fig. 3C, GFP expression is dramatically reduced in *Eomes*\(^{\text{GFP\DeltaVPE/+}}\) EBs as compared to *Eomes*\(^{\text{GFP+}}\) EBs. The VPE deletion results in markedly reduced expression to 42\% of the control *Eomes*\(^{\text{GFP+}}\) EBs (student’s t-test \(p=0.05\)) (Fig. 3D).

These heterogenous EB cultures contain mixtures of cardiac mesoderm, DE and VE Eomes\(^{+}\) cell populations. To investigate the impact of the VPE deletion *in vivo*, we generated *Eomes*\(^{\text{GFP\DeltaVPE/+}}\) mice and examined expression during gastrulation. GFP expression in *Eomes*\(^{\text{GFP\DeltaVPE/+}}\) embryos recapitulates domains of the *Eomes*\(^{\text{GFP+}}\) control embryos at E6.5, in the ExE, PS, nascent mesoderm, and VE (Fig. 3E,F). The VPE deletion reduced expression levels but tissue specific expression patterns were unperturbed. Similar conclusions were reached by whole-mount *in situ* hybridisation (WISH) experiments examining *Eomes* mRNA expression in *Eomes*\(^{\text{ΔVPE/ΔVPE}}\) embryos (Fig. S4E). Thus, reduced *Eomes* transcription (~50\%) as in *Eomes*\(^{+/−}\) or *Eomes*\(^{\text{ΔVPE/ΔVPE}}\) embryos is sufficient to promote A-P axis specification and gastrulation. However, as shown above, further reduced expression (~25\%) in *Eomes*\(^{\text{ΔVPE−}}\) embryos results in gastrulation defects.

**FoxH1-independent Nodal/Smad2/3 signals regulate VPE activity**

*Eomes* activation in the VE and PS depends on Nodal/Smad signals (Brennan et al., 2001; Nowotschin et al., 2013). To investigate Nodal/Smad requirements in cultured EBs, we used the small molecule SB-431542 (SB), a potent inhibitor of type 1 Activin receptor like kinases
4, 5 and 7. As expected, in control cultures maximal *Eomes* expression was detectable between d3.5 and d4 (Fig. 4A). *Eomes* expression was dramatically reduced in cultures treated with the SB inhibitor from d3, and by d4 is severely compromised to just 2% of that seen in controls (Fig. 4A). These results confirm that Nodal signaling is required to induce *Eomes* expression during the transition from pluripotency to lineage commitment. Additionally when we compared Smad2/3 ChIP-seq datasets in ESC and DE cultures (Yoon et al., 2015), we found evidence for Smad2/3 occupancy at the VPE specifically in DE cultures (Fig. 4B). These observations strengthen the idea that Nodal/Smad signals controlling *Eomes* expression activate transcription via the VPE.

It is well known that the forkhead transcription factor FoxH1 functions as a Smad2/3 co-factor governing Nodal/Smad target gene expression (Attisano et al., 2001; Izzi et al., 2007). FoxH1 has been proposed to act as a pioneer factor and recruit Smad2/3 complexes to switch enhancers, activated as ESC transition to DE fates (Beyer et al., 2013; Cirillo et al., 2002; Cirillo and Zaret, 1999; Kim et al., 2011). Interestingly, the VPE Smad2/3 peak also contains a conserved FoxH1 binding motif. Moreover, the VPE region is co-bound by FOXH1, SMAD2/3, and SMAD4 in human DE cultures (Fig. S6) (Beyer et al., 2013; Brown et al., 2011; Kim et al., 2011; Teo et al., 2011). Consistent with the idea that FoxH1 cooperatively activates *Eomes* expression via the VPE, homozygous null *FoxH1* embryos phenocopy the *EomesΔVPE* embryos, displaying either defective AVE formation prior to gastrulation, or disturbances in APS specification at later stages (Hoodless et al., 2001; Yamamoto et al., 2001).

To directly evaluate FoxH1 functional contributions, we analysed *Eomes* expression at E6.5 and E7.5 in the context of FoxH1−/− mutant embryos (Fig. 4C). In mutants with AVE/DVE defects at E6.5 *Eomes* is expressed in the thickened VE at the distal tip of the embryo, and at E7.5 in the chorion and proximal epiblast. FoxH1 mutants with APS defects express *Eomes* in the ExE and PS. *Eomes* is clearly expressed in both classes of FoxH1 mutant embryos. Slightly reduced levels in the PS can be explained due to the loss of FoxH1-dependent activation of the auto-regulatory ASE Nodal enhancer (Norris et al., 2002). In striking contrast to *Eomes/Nodal* double heterozygotes (Arnold et al., 2008a), we found no evidence here for *Eomes* and FoxH1 genetic interactions. Indeed, *Eomes* and FoxH1 compound mutant mice are fully viable (Fig. 4D). Finally, to confirm that VPE activity is FoxH1 independent, we examined expression of the VPE-LacZ transgene in FoxH1 mutant
embryos. LacZ staining is detectable throughout the epiblast at E6.5 (Fig. 4E), and also in the thickened VE at the distal tip. FoxH1 function is nonessential for VPE-LacZ reporter activity. Thus, we conclude that Nodal/Smad signals activate Eomes expression in a FoxH1-independent manner raising the possibility that other forkhead family members may recruit Smad2/3 complexes during Eomes induction in vivo.

Characterisation of the Eomes 3D regulatory chromatin compartment during endoderm differentiation

The finding that the VPE targeted deletion partially reduces but fails to completely eliminate Eomes expression, strongly suggests that additional regulatory elements contribute to transcriptional output of the locus. Enhancer interactions with target promoters have been analysed by chromatin conformation capture techniques (de Wit and de Laat, 2012). We took advantage of the recently developed Next Generation (NG) Capture-C methodology (Davies et al., 2016) to screen for Eomes regulatory enhancer elements. During DE differentiation Eomes expression increased by ~600 fold (Fig. S7B) resulting in activation of the Eomes target genes, Lhx1 and Foxa2 (Fig. S7C) (Nowotschin et al., 2013; Teo et al., 2011).

NG Capture-C using viewpoints from the PSE_a and PSE_b exhibited promoter interactions in ESC (Fig. S8) when analysed with FourCseq (Klein et al., 2015). These interactions were marginally reduced in DE. However the overall change was not statistically significant. By contrast NG Capture-C revealed significant interactions between the VPE and the Eomes promoter in both ESC and DE cells (Fig. S8). Thus, the locus appears to be primed for activation prior to expression.

Next, performing Capture-C using a viewpoint from the Eomes promoter revealed that the Eomes locus, together with an upstream 300kb gene desert, and its neighboring genes Azi2 and Cmc1, occupies a discrete ~500kb chromatin compartment (Fig. 5A). This region contains numerous CTCF binding sites (Handoko et al., 2011). Consistent with CTCF-mediated chromatin loops forming the compartment boundaries, motif analysis suggests that the outermost binding sites face inwards (Fig. 5A). This compartment structure is readily detectable in both ESC and DE cells but is completely absent in control terminally differentiated erythrocytes lacking Eomes expression (Fig. 5A, Fig. S9). Comparison of the NG Capture-C data from ESC and DE, in which the Eomes locus is transcriptionally silent or
active, respectively, demonstrates that the compartment is highly stable. Moreover there were no detectable changes in long-range promoter interactions within the compartment (Fig. S10).

To map changes in regions of open chromatin associated with Eomes activation and identify potential novel DE enhancers within the compartment we performed ATAC-seq. We identified 85,581 total peaks in ESC and DE, and of these 19% were gained and 32.5% lost during differentiation (Fig. S9). Within the Eomes compartment we identified 6 regions that show increased accessibility in DE, including the VPE and the PSE_a as well as four additional sites at -93kb, -45kb, -38kb and +9kb relative to the Eomes TSS (Fig. 5B).

Next, we examined Smad2/3 binding across the compartment (Yoon et al., 2015). Smad2/3 occupancy was detectable in DE but not in ESC at all six of the differentially accessible sites (Fig. 5B). These findings demonstrate the Eomes locus is organised into a large 3D regulatory chromatin compartment in pluripotent ESC that is maintained upon DE differentiation. Global structural changes are not required for Eomes induction during DE differentiation. Rather, transcriptional activation seems to reflect increased chromatin accessibility and Smad2/3 recruitment at DE enhancers. The -95kb and -45kb regions, and to a lesser extent the -38kb region, are associated with poised and active enhancer marks as cells transition from ES to Epi to MES states respectively (Fig. S11). Additionally recently published TF ChIP-seq data demonstrate that the -45kb ATAC-seq peak together with the PSE_a and VPE are co-bound by Tcf3 in DE (Wang et al., 2017), suggesting that both Nodal and Wnt signaling converge on these enhancer regions during gastrulation (Ben-Haim et al., 2006). Consistent with its activities as a key Eomes regulatory element during DE specification, the VPE is also bound by Otx2 and Lhx1 in EpiLC and mesendoderm cultures respectively (Buecker et al., 2014; Costello et al., 2015).

**Foxa2 and Lhx1 promoters form long-range interactions in polycomb bodies**

The forkhead TF Foxa2 and the LIM domain homeobox TF Lhx1 function together with Eomes as master regulators of APS cell fates (Ang and Rossant, 1994; Costello et al., 2015; Perea-Gomez et al., 1999; Shawlot and Behringer, 1995). One possible model is that this pre-configured genomic structure might be a common feature shared by endoderm specific transcriptional factors (Fig. S7C). As for Eomes, Capture-C of the Foxa2 and Lhx1 promoters demonstrates localisation within pre-formed compartments (both ~350kb) in ESC, but not
erythrocytes where the genes are inactive (Fig. 6A,B). However, these Foxa2 and Lhx1 compartments were found to undergo significant rearrangements during DE differentiation (Fig. 6A,B). Unlike Eomes, in ESC Lhx1 and Foxa2 promoters both make long-range contacts with neighboring developmental genes lying outside the compartment boundaries (Fig. 6A,B). These long-range interactions range from 370kb to 1.8Mb in size and are almost entirely specific to gene promoters (Table S3), and are lost as cells acquire a DE fate (Fig. 6A,B).

Both Foxa2 and Lhx1 are repressed by polycomb in ESC (Leeb et al., 2010). Examination of published ESC ChIP-seq data-sets for Polycomb components Ezh2, Suz12 (PRC2) and Ring1b (PRC1) (Chen et al., 2008; Ku et al., 2008) as well as the polycomb repressive mark H3K27me3 (Yue et al., 2014) showed they are present at all of the promoters of the adjacent genes with which Lhx1 and Foxa2 interact (Fig. 6), suggesting that these genes are present in Polycomb bodies (Pirrotta and Li, 2012). Interestingly, these Polycomb repressive components are also present at the Eomes promoter in ESC, but we found no evidence for long-range interactions with gene promoters lying outside the compartment (Fig. S10). Collectively, results above demonstrate that three essential TFs required for cell fate specification, Eomes, Foxa2, and Lhx1, were found to exhibit distinct modes of 3D chromatin organisation during differentiation.

Discussion

The spatiotemporal expression of key lineage specifying transcription factors (TF) is tightly controlled during early mouse development to ensure correct cell fate decisions. Interactions of cell-type specific cis-acting enhancer elements with gene promoters, within topologically discrete chromatin compartments, directs developmentally regulated patterns of expression (de Laat and Duboule, 2013). Our recent studies demonstrate that the T-box TF Eomes, dynamically expressed in the VE, ExE and PS during gastrulation, acts downstream of the Nodal signaling pathway as an essential master-regulator of the DE and cardiac mesoderm cell lineages. Here, we exploit transgenic reporter assays, targeted deletion, and NG Capture-C strategies to investigate the regulatory landscape at the Eomes locus.

We demonstrate in gain of function experiments that conserved proximal cis-regulatory elements, namely the so-termed PSE (comprising of PSE_a and PSE_b) and the VPE, have the ability to drive reporter activity in the PS, or VE and PS, respectively. The conserved
*Eomes* PSE_b region, representing an archetypal poised developmental enhancer in both human and mouse ESC, was recently shown to be activated upon mesendoderm induction in response to Nodal (Smad2/3, FoxH1) and Wnt (β-cat) signaling pathways (Beyer et al., 2013; Brown et al., 2011; Buecker and Wysocka, 2012; Estaras et al., 2015; Funa et al., 2015; Kartikasari et al., 2013; Kim et al., 2011; Rada-Iglesias et al., 2011). However, surprisingly our targeted deletion experiments demonstrate that this switch enhancer, and the adjacent PSE_a, are dispensable for correct developmentally regulated *Eomes* expression in the early embryo. Moreover, mutant mice that entirely lack this genomic region develop normally and are viable and fertile.

*Eomes* is required for the maintenance and migration of the AVE (Nowotschin et al., 2013). Additionally, robust expression in the PS is essential for formation of APS progenitors (Arnold et al., 2008a). The present results demonstrate that the VPE activates expression in both the AVE and PS, and makes important functional contributions governing Eomes activities during gastrulation. We found that removal of this element halves transcriptional output from the locus as assessed *in vitro*. Moreover, *Eomes<sup>ΔVPE</sup>* embryos exhibit pleiotropic tissue defects due to compromised specification of AVE or APS, that closely resemble those caused by defective Nodal signaling or loss of the Smad2/3/4 co-factor, *FoxH1* (Arnold et al., 2008a; Hoodless et al., 2001; Norris et al., 2002; Yamamoto et al., 2001).

Our NG Capture-C experiments revealed that the VPE directly interacts with the *Eomes* promoter in both ESC and DE. Moreover the *Eomes* locus lies within a large pre-formed 3D regulatory chromatin compartment in pluripotent ESC that is maintained upon differentiation to DE. Thus activation of the locus occurs in the absence of remodeling long-range interactions. In contrast, previous studies of mouse and human ESC implicate *de novo* enhancer-promoter interactions during DE and mesendoderm differentiation (Estaras et al., 2015; Kartikasari et al., 2013). These inconsistencies probably reflect technical differences since a target lead (one-versus-some) 3C PCR technique was used previously, as compared to the unbiased (one-versus-all) NG Capture-C sequencing approach exploited here.

NG Capture-C analysis of the direct Eomes targets, *Foa2* and *Lhx1*, known to regulate APS fates, demonstrates they similarly occupy discrete regulatory compartments in transcriptionally silent ESC. However, in contrast to *Eomes*, *Foa2* and *Lhx1* promoters display contacts with polycomb associated gene promoters lying far outside their compartments. These associations are specifically lost during DE differentiation (Fig. 7).
Promoter-promoter interactions within ESC are often occupied by polycomb repressive complexes (PRC) that organise the 3D chromatin structure into polycomb bodies to silence gene expression (Denholtz et al., 2013; Schoenfelder et al., 2015; Sexton et al., 2012; Williamson et al., 2014). These epigenetic barriers are thought to block lineage-specifying gene activation and thus prevent precocious differentiation. We demonstrate here that in contrast to Foxa2 and Lhx1 the Eomes locus exhibits a distinct mode of regulation. Rather, in the absence of polycomb mediated repressive contacts, the Eomes promoter can rapidly respond to dynamic signaling cues during gastrulation (Fig. 7).

Considerable evidence suggests that stable enhancer-promoter interactions within pre-formed chromatin compartments initiate transcription through the release of paused polymerase (de Laat and Duboule, 2013; Ghavi-Helm et al., 2014; Jin et al., 2013; Williamson et al., 2016). We found that promoter-enhancer interactions are relatively stable. However our ATAC-seq experiments reveal significant changes in open chromatin regions during DE differentiation. We identified several candidate enhancers within the Eomes compartment, that display increased chromatin accessibility and are greatly enriched for Smad2/3 occupancy upon DE differentiation (Yoon et al., 2015). Moreover, we confirm that Smad2/3 is required for Eomes activation, as inhibition of receptor mediated Nodal/Smad2/3 signaling blocks transcription. Smad2/3 associations with the histone demethylase Jmjd3 are known to be required for the activation of Nodal target genes (Dahle et al., 2010; Kartikasari et al., 2013). Jmjd3 activates poised developmental genes by removing promoter-proximal H3K27me3 and releasing paused polymerase (Chen et al., 2012). We propose that the poised chromatin architecture at the Eomes locus is permissive for rapid transcriptional induction in response to localised Nodal signaling during gastrulation, primarily via enhancer binding of Smad2/3/Jmjd3 complexes to release promoter-paused polymerase.

The 3C technologies developed over the past two decades have provided important new insights into the regulatory chromatin landscapes that orchestrate tissue-specific transcription. Here, we characterise for the first time cis-regulatory elements that activate Eomes expression during gastrulation, and describe the higher order chromatin architecture of the locus. We speculate that the pre-formed chromatin compartment and the absence of additional epigenetic safeguards prior to expression facilitates the rapid induction of Eomes expression in response to dynamic signaling cues at the onset of gastrulation. However, the stage of embryonic development that these compartments are established, and later
dismantled, remains elusive. Future studies will investigate whether these enhancers and permissive chromatin configuration are tissue-invariant and may also control cell type specific *Eomes* expression governing cell fate decisions at other sites such as the developing cortex, and adult NK and CD8+ T cell lineages (Arnold et al., 2008b; Gordon et al., 2012; Pearce et al., 2003).
Materials and Methods

Animals and PCR genotyping

Eomes^{GFP/+} (Arnold et al., 2009) and FoxH1^{+/−} (Hoodless et al., 2001) strains were genotyped as described. Eomes^{PSE/+}, Eomes^{PSE,b/+}, Eomes^{VPE/+} and Eomes^{GFP/VPE/+} strains were generated from targeted ES cell clones using standard methods (Arnold et al., 2009) (Fig. S2-S5, Supplementary Methods), and maintained on a mixed 129Sv/Ev/C57BL/6 background. To generate PSE.LacZ and VPE.LacZ transgenic constructs the 4.6 kb HincII – KpnI PSE fragment and a 696bp PCR amplified VPE sequence (Table S1), were cloned upstream of a hsp68 promoter, LacZ cassette and SV40 polyA signal (Sasaki and Hogan, 1996). Zygotes were injected with NotI linearised plasmid and transferred into pseudo-pregnant foster females. Embryos were either collected at E6.5-E7.5 or used to establish stable transgenic mouse lines. PCR genotyping primers are listed in Table S1. All animal experiments were performed in accordance with Home Office (UK) regulations and approved by the University of Oxford Local Ethical Committee.

ESC differentiation

ES cell lines were maintained in DMEM (Invitrogen) supplemented with 15% fetal calf serum (Gibco), 1% Penicillin/Streptomycin (Invitrogen), 0.1mM 2-mercaptoethanol (Sigma), 1% Glutamine (Invitrogen), 1% MEM Non-essential amino acids (Gibco), 1mM Sodium Pyruvate (Sigma), 1000U/ml LIF (ESGRO) on gelatin coated plates.

For analysis of GFP reporter expression wild type (CCE), Eomes^{GFP/VPE/+} and Eomes^{GFP/+} ES cells were seeded as 10 µl hanging drops (1x10⁴ cells/ml) in the absence of LIF to induce EB formation. After 2 days EBs were transferred to suspension culture. For SB inhibition experiments, ES cells were seeded in suspension at low density (1x10⁴ cells/ml) in the absence of LIF to form EBs. On day 3 EBs were cultured in the presence or absence of 10 µM SB431542 inhibitor (Tocris). For DE differentiation, ES cells were induced to form EBs in suspension as described above, but were transferred on day 2 into N2B27 medium (Cellartis) supplemented with 20ng/ml ActivinA (R&D systems) and 20ng/ml EGF (Peprotech) to induce DE differentiation (Morrison et al., 2008). For Capture-C, ChIP-seq, and ATAC-seq experiments EBs were dissociated by incubation with 0.25% trypsin (Gibco) for 3 min at 37°C with constant agitation followed by gentle pipetting to obtain a single cell suspension.
**RNA analysis**

RNA was isolated from using Qiashredder homogenizer (Qiagen), RNeasy mini kit (Qiagen) and RNase-Free DNase Set (Qiagen). RNA was reverse transcribed to cDNA using Superscript III First Strand Synthesis System (Life Technologies) and qRT-PCR was carried out in triplicate using SYBR-green kit (Qiagen) on a Rotagene cycler (Qiagen) with primers listed in Table S1. Relative gene expression was normalised to *Gapdh* and calculated as $2^{\Delta\Delta Ct}$.

**In situ hybridisation, X-gal staining and Immunofluorescence**

Whole-mount *in situ* hybridisation (WISH) was performed according to published protocols (Behringer et al., 2013). LacZ activity was visualised by whole-mount X-gal staining as described (Behringer et al., 2013). Whole-mount WISH and X-gal stained embryos were photographed after clearing in 80% glycerol.

For immunofluorescence, embryos were fixed overnight in 1% PFA. EBs were fixed in 4% PFA for 30 min at room temperature. Samples were washed in 0.1% Triton-X in PBS, permeabilised in 0.5% Triton-X in PBS for 15 min, washed in 0.1% Triton-X in PBS, then blocked in 0.1% Triton-X, 0.2% BSA, 5% donkey serum in PBS for 2 hours at room temperature. Samples were incubated with primary antibodies (Table S2) overnight at 4°C, washed, incubated with secondary antibodies or Phalloidin AlexaFluor 633 stain (A22284; Invitrogen) in block solution for 2 hours at room temperature, counterstained with DAPI and mounted in Vectashield (Vector Laboratories) on chamber slides (LabTek). Images were acquired using an Olympus FV1000 inverted confocal microscope.

**Flow cytometry**

Day 4 EBs were incubated in 0.25% trypsin for 5 min at 37°C and dissociated into single cells using a 20-guage needle. FACS analysis was performed using a BD FACSCalibur 4 (BD Biosciences) and data analysed using FlowJo.

**ATAC-seq**

Tagmentation and indexing of single cell suspensions of ESC, DE and erythrocytes from phenylhydrazine treated mice (Davies et al., 2016) was performed as previously described (Buenrostro et al., 2013; Hay et al., 2016). Samples were sequenced using a 75-cycle paired-end kit on the Illumina NextSeq platform.
**ChIP-seq**

Single cell suspensions \((5 \times 10^6)\) were cross-linked in 1% formaldehyde for 15 minutes at room temperature and processed using standard methods. Briefly, cells were lysed on ice for 20 minutes \((5\text{mM PIPES, 85mM KCl, 0.5% Igepal-CA 630})\), and pelleted nuclei lyzed \((50\text{mM Tris-HCl, 10mM EDTA, 1% SDS})\). Sonicated chromatin was incubated overnight with anti-H3K4me3 \((2\mu\text{l; 07-473; Millipore})\) and Protein A/G Dynabeads \((\text{Invitrogen})\). Beads were washed with RIPA buffer variants \((10\text{mM Tris-HCl, 1mM EDTA, 0.5mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Sodium Deoxycholate})\): RIPA, High Salt RIPA \((500\text{mM NaCl})\), RIPA with \(250\text{mM LiCl}\) and T.E. Buffer before RNase A \((\text{Roche})\) and Proteinase K \((\text{Thermo Fisher})\) treatment. Phenol-chloroform extracted DNA was indexed using NebNext Ultra II \((\text{New England BioLabs})\), multiplexed and sequenced using a 75-cycle paired-end kit on the Illumina NextSeq platform.

**ATAC-seq and ChIP-seq analysis**

ATAC-seq and ChIP-seq data were analysed as described \((\text{Hay et al., 2016})\) using a custom pipeline \((\text{http://userweb.molbiol.ox.ac.uk/public/telenius/PipeSite.html})\). Sequenced reads were aligned using Bowtie to the mm9 build of the mouse genome. Genomic browser tracks were generated from pooled data from multiple replicates and normalized per million mapped reads using a custom Perl script. Peak detection was performed with the MACS2 \((\text{Feng et al., 2012})\). For differential analysis, a union set of peaks for each cell type generated from \(\geq 2\) peak calls per site. Peaks were filtered for high ploidy regions using MIG Viewer \((\text{McGowan et al., 2013})\). CTCF-motifs were identified using the FIMO function of MEME Suite \((\text{Bailey et al., 2009; Grant et al., 2011})\).

**NG Capture-C and analysis**

NG Capture-C was performed as described \((\text{Davies et al., 2016})\) on single cell suspensions of ESC, DE or erythrocytes. Samples were indexed for multiplexing and co-capture of enhancers or promoters using biotinylated 120mers \((\Sigma\text{Sigma, IDT})\) designed with the CapSequm webtool \((\text{http://apps.molbiol.ox.ac.uk/CaptureC/cgi-bin/CapSequm.cgi})\) \((\text{Hughes et al., 2014})\) and pooled to a final concentration of 2.9nM \((\text{Table S4})\). Captured material was pooled and sequenced using the Illumina NextSeq platform with 150-bp paired-end reads \((300\text{ cycle kit, Illumina})\). Reads were mapped using Capture-C scripts \((\text{https://github.com/telenius/captureC/releases})\), and analyzed as previously described \((\text{Hay et...})\).
al., 2016), and additionally with FourCSeq (Klein et al., 2015) and DESeq2 (Love et al., 2014).

Acknowledgements

We thank Julie Baker for valuable discussions during the initial stage of the project, Ben Davies and Chris Preece (Wellcome Trust Centre for Human Genetics) and Jonathan Godwin (Department of Biochemistry, University of Oxford) for generating transgenic mice, the Dunn School Bioimaging Facility, Nigel Rust for flow cytometry, Xin Sun for help with gene targeting, and Thomas Clague for genotyping assistance.

Competing Interests

The Authors declare no competing or financial interests

Author Contributions

C.S.S, I.C., E.K.B. and E.J.R. designed the project; C.S.S., D.J.D., M.E.G. and E.J.R. performed the experiments; C.S.S., D.J.D, J.T., D.R.H., J.R.H, E.K.B. and E.J.R. analysed and interpreted the data; C.S.S., D.J.D., E.K.B and E.J.R. wrote the paper.

Funding

This work was supported by a Wellcome Trust Grant [WT 102811 to E.J.R.] an Edward Penley Abraham studentship [to C.S.S.], and by a Wellcome Trust Strategic Award [WT 106130 to J.R.H. and D.R.H] and a Medical Research Council Award [4050189188 to J.R.H. and D.R.H.] E.J.R. is a Wellcome Trust Principal Research Fellow.

Data Availability

ChIP-seq, ATAC-seq and NG Capture-C data have been deposited in NCBI GEO (submission in process). Accession numbers of published ChIP-seq data sets used in this study are listed in Supplementary Table S5.

Supplementary Information

Supplementary information in the form of 11 Figures and 5 Tables accompanies this manuscript.
References


Figure 1. Mapping proximal *Eomes* enhancers active at gastrulation.

(A) ChIP-seq of H3K4me1, H3K27me3 and H3K27ac and DNasel hypersensitivity (HS) in ESC, epiblast like cells (EpiLC) and mesoderm (MES) (Alexander et al., 2015; Buecker et al., 2014; Consortium, 2012) identify potential proximal *Eomes* enhancers activated during differentiation. The PSE cluster and VPE regions are highlighted in grey. (B-C) X-gal stained transgenic embryos expressing enhancer driven LacZ reporters. (B) PSE reporter activity is
confined to the primitive streak (PS) at early- (ES), mid- (MS) and late-streak (LS) stages of gastrulation (2/4 transgenic mouse lines). (C) VPE reporter activity detectable in the proximal posterior epiblast (Epi) at pre-streak (PrS) stage, the PS at MS stage, becomes restricted to the anterior PS (APS) and lost at LS stage. Between PrS stage and LS stage VPE activity is also detectable in the anterior visceral endoderm (AVE) (2/6 transgenic mouse lines).
Figure 2. Targeted deletions of proximal enhancers show that only the VPE is required for proper gastrulation.

(A) Targeted deletions of the 5kb ΔPSE, 2kb ΔPSE_b, and 0.7kb ΔVPE generated by homologous recombination (Fig. S2-S4). (B) Genotypes of weanlings from heterozygous enhancer deletion intercrosses. Homozygous deletion of proximal enhancers does not affect viability (ΔPSE p=0.9, ΔPSE_b p=0.4, ΔVPE p=0.5, Chi-square test). (C) Genotypes of weanlings from heterozygous null and homozygous enhancer deletion matings. EomesΔVPE/− animals are significantly underrepresented compared with littermate controls (ΔPSE p=0.87, ΔPSE_b p=0.7, ΔVPE ***p=0.001, Chi-square test). (D) Whole-mount in-situ hybridisation of EomesΔVPE/− embryos. Class I mutants exhibit failure in A-P axis specification, and class II
display APS defects. At E6.5 in class I mutants expression of the AVE marker \textit{Hex} is confined to the distal VE (n=4/10 \textit{Eomes}^{ΔVPE/-} embryos analysed). At E7.5, the mesoderm marker \textit{Brachyury} (n=2/5) and DE marker \textit{Foa2} (n=3/7) are mis-localised proximally. In class II mutants \textit{Hex} marks the AVE, \textit{Brachyury} expression fails to extend distally (n=3/5), while the \textit{Foa2} domain is confined to the APS and the DE domain is lost (n=3/7). Consistent with failure to specify DE in both mutant classes expression of \textit{Af}p+ VE cells fails to disperse proximally (for Class I and Class II, n=2 and n=2 of 7 \textit{Eomes}^{ΔVPE/-} embryos analysed, respectively). At E9.5 class II mutants display venture closure and neural tube defects, fused or malformed somites, loss of \textit{Otx2}+ forebrain tissue, and an anterior truncation of the \textit{Shh} midline (n=3/3 viable morphologically abnormal \textit{Eomes}^{ΔVPE/-} embryos recovered). Scale bars: 100 μm.
Figure 3. VPE deletion profoundly reduces the level of \textit{Eomes}^{\text{GFP}} reporter expression.

(A) Configuration of the \textit{Eomes}^{\text{GFP}} and \textit{Eomes}^{\text{GFPΔVPE}} alleles (Fig. S5). (B) Schematic of embryoid body (EB) differentiation protocol. (C-D) Flow cytometry analysis of wild type, \textit{Eomes}^{\text{GFP/+}} and \textit{Eomes}^{\text{GFPΔVPE/+}} day 4 EBs. (C) Representative histograms showing wild type, two independently targeted \textit{Eomes}^{\text{GFP/+}} and two \textit{Eomes}^{\text{GFPΔVPE/+}} clones. (D) Average GFP intensity in \textit{Eomes}^{\text{GFP/+}} (n=4) and \textit{Eomes}^{\text{GFPΔVPE/+}} (n=4) cultures. Deletion of the VPE significantly reduces expression to 42\% of the intact \textit{Eomes}^{\text{GFP}} reporter (p=0.05, Student’s t-test). Error bars represent ± s.e.m. (E-F) Confocal images of \textit{Eomes}^{\text{GFP}} and \textit{Eomes}^{\text{GFPΔVPE}} reporter expression in E6.5 embryos stained with anti-GFP antibody, DAPI (DNA) and Phalloidin (F-actin). Domains of reporter expression are not perturbed by VPE deletion.
Figure 4. VPE expression is regulated by Smad2 and independently of FoxH1.

(A) RT-qPCR analysis of Eomes mRNA expression during EB differentiation. SB-431542 (SB) inhibition of Nodal/Smad2 signaling from day 3 onwards significantly reduces Eomes expression at d3.5 and d4 of differentiation (*p<0.05, **p<0.001, Student’s t-test, n=3). Error bars represent ±s.e.m. (B) ChIP-seq of Smad2/3 in definitive endoderm (DE) reveals binding to the VPE (Yoon et al., 2015), overlapping a predicted and conserved binding site for FoxH1, identified with JASPAR at >80% confidence (Mathelier et al., 2016). (C) Whole-mount in situ hybridisation of Eomes mRNA in control and FoxH1 null embryos. Eomes is expressed in both AVE and APS defective FoxH1 mutant subtypes at E6.5 and E7.5. (D) Genotypes of weanlings from Eomes and FoxH1 intercross matings. Compound heterozygotes do not show reduced viability (p=0.5, Chi Square test). (E) VPE-LacZ reporter activity both in the VE and epiblast is retained in FoxH1 mutant embryos at E6.5. Scale bars: 100 μm.
Figure 5. *Eomes* is regulated by Smad2/3 binding in a preformed compartment.

(A) NG Capture-C interaction profiles of the *Eomes* promoter (chr9:117,683,476-118,771,067) from erythrocytes (grey), ESC (blue) and DE (green). Tracks show mean interactions of normalized biological replicates (n=3), and DESeq2 significant differences between DE and ESC (-log(P_{adj}); p≤0.05). The *Eomes* compartment as determined by boundaries of strong promoter interactions with CTCF orientation (arrowheads) based upon binding in ESC (Handoko et al., 2011). Histone modifications for H3K4me3 (DE, n=3) shows promoter regions. (B) Zoom in panel of the region of the Eomes compartment showing highest association with the promoter, from chr9: 118,252,500-118,405,500. Open chromatin was generated using ATAC-seq in ESC and DE (n=3), with the addition of MACS2 called peaks annotated beneath each ATAC-seq track and Smad2/3 ChIP-seq in ESC (blue) and DE (green) (Yoon et al., 2015). Regions of chromatin accessibility unique to ESC (-73kb) and those associated with Smad2/3 occupancy in DE (-93kb, -45kb, -38kb, PSE_a, VPE and +9kb) are highlighted.
Figure 6. *Foxa2* and *Lhx1* form long-range interactions with polycomb repressed promoters.

NG Capture-C interaction profiles of the *Foxa2* (A) and *Lhx1* (B) promoters from erythrocytes (grey), ESC (blue) and DE (green) with chr2: 146,001,500-148,328,000 and chr11: 82,700,000-85,808,000 shown respectively. Tracks show mean interactions of normalized biological replicates (n=3), subtraction of ESC from DE (Subtr.) and DESeq2 significant differences between DE and ESC (-log(Padj); p≤0.05). Peaks of strongest interactions in ESC (shaded boxes) were manually identified and highlighted. Compartments were determined by boundaries of strong (continuous) promoter interactions. Location of the Polycomb Repressor Complexes components (Ezh2, Suz12, Ring1b) and associated histone modification (H3K27me3) in ESC are shown (Ku et al., 2008; Mikkelsen et al., 2007).
Figure 7. Eomes, Foxa2, and Lhx1 exhibit distinct modes of 3D chromatin organisation during differentiation.

(A) In ESC Eomes, Foxa2 and Lhx1 are organised into pre-formed chromatin compartments.

(B) Unlike Eomes, both Foxa2 and Lhx1 promoters form extra-compartmental contacts with other polycomb-repressed gene promoters.

(C) Model for Eomes activation. The poised chromatin architecture at the Eomes locus is permissive for rapid transcriptional induction in response to localised Nodal signaling during gastrulation, primarily via enhancer binding of Smad2/3 complexes.
Supplemental Material

Supplementary Methods

Generation of targeted alleles

Targeting vectors containing 5’ and 3’ arms homologous to the Eomes locus, a FLP recognition target (FRT) flanked PGK.Neomycin selection cassette and a PGK.DTA (diphtheria toxin A) cassette for negative selection. The ΔVPE targeting vector was generated by recombineering using oligos listed in Table S1, designed to delete 656bp of the VPE. The ΔPSE_b vector includes a 5’ 5.8kb SpeI-EcoRV fragment and a 3’ 5kb KpnI-EcoRI fragment of the Eomes locus, and deletes 2019bp of PSE_b. The PSE vector comprises a 5’ 5.6kb AatII-Bsu36I fragment, where the upstream AatII site was introduced by PCR (Table S1), and a 3’ 5kb KpnI-EcoRI fragment of the Eomes locus, resulting in deletion of 4775bp of the PSE. XhoI (PSE, PSE_b) or ApaLI (VPE) linearized vectors (15ug) were electroporated into CCE ES cells, and Eomes^{GFP+} cells. Screening of drug resistant ESC clones was carried out by Southern blot analysis with the restriction enzymes and probes summarised in Fig. S2, S3, S4 and S5 using standard protocols (Behringer et al., 2013).
Supplemental References


Figure S1: PSE and VPE enhancers are conserved in human

(A) DNaseI hypersensitivity (HS) and ChIP-seq of CTCF in ESC (Consortium, 2012). Conservation at the Eomes locus across vertebrates (UCSC browser, mm9). Boxes indicate PSE_a, PSE_b, and VPE enhancer regions, highly conserved amongst mammals. Arrows indicate CTCF bound regions downstream of the VPE. (B) ChIP-seq of H3K27ac and H3K4me1 histone modifications at the Eomes locus in human ESC (hESC), definitive endoderm (hDE) and human gut tube (hGT) (UCSC browser, hg18) (Wang et al., 2015). Homologous regions to the mouse VPE and PSE are associated with these active enhancer marks and are highlighted in grey. Human VPE, PSE_a and PSE_b (hVPE, hPSE_a, hPSE_b)
Figure S2: Targeted deletion of the PSE_b sub-region

(A) Targeting strategy to delete the 2kb PSE_b region (chr9:118379552-118381570; mm9) by homologous recombination. Southern blot restriction digest used for screening are indicated together with the probes (green and blue bars) and expected fragment sizes for the correctly targeted allele. EcoRI (E), Scal (S), FLP-recombinase recognition site (FRT) site, Neomycin resistance cassette (Neo), Diphtheria toxin A cassette (DTA). Red arrows indicate primers for verifying FLP excision. (B,C) Southern blot of successfully targeted ESC clones. (D) PCR genotyping of Eomes<sup>ΔPSE_b</sup> mice.
Figure S3: Targeted deletion of the PSE region

(A) Targeting strategy to delete the 5kb PSE region (chr9:118376796-118381570; mm9) by homologous recombination. Southern blot restriction digest used for screening are indicated together with the probes (green and blue bars) and expected fragment sizes for the correctly targeted allele. KpnI (K), ScaI (S), FLP-recombinase recognition site (FRT) site, Neomycin resistance cassette (Neo), Diphtheria toxin A cassette (DTA). Red arrows indicate primers for verifying FLP excision. (B,C) Southern blot of successfully targeted ESC clones. (D) PCR genotyping of EomesΔPSE mice.
Figure S4: Targeted deletion of the VPE region

(A) Targeting strategy to delete the 0.7kb VPE region (chr9:118395625-118396280; mm9) by homologous recombination. Southern blot probes (red and blue bars), restriction digests and expected fragment sizes are indicated for the targeted and excised alleles. BamHI (B), KpnI (K), FLP-recombinase recognition site (FRT) site, Neomycin resistance cassette (Neo), Diphtheria toxin A cassette (DTA). Red arrows indicate primers for verifying FLP excision. (B) Southern blot of targeted ESC clones. (C) Southern blot to identify excision of Neo cassette in targeted ESC clones. (D) PCR genotyping ΔVPE allele in mice derived from Eomes<sup>ΔVPE/+</sup> intercrosses. (E) Whole-mount in situ hybridisation of Eomes transcripts at early mid-streak stages shows Eomes expression domains are unaltered in Eomes<sup>ΔVPE/ΔVPE</sup> compared to wild type embryos.
**Figure S5: Generating Eomes\textsuperscript{GFP} allele lacking the VPE region**

(A) Heterozygous Eomes\textsuperscript{GFP/+} (Arnold et al., 2009) ESC were re-targeted using the same construct and primary screening strategy as used to delete the VPE. Southern blot strategy used to distinguish targeting the VPE region in either the GFP or wild type alleles, and expected fragment sizes are indicated. SpeI (S). (B) Southern blot showing two different genotypes of successfully targeted clones; Eomes\textsuperscript{GFPΔVPE/+} and Eomes\textsuperscript{GFPΔVPE/ΔVPE}. (C) PCR genotyping of Eomes\textsuperscript{GFPΔVPE/+} mice.
Figure S6: Regulation of the VPE by Nodal signaling

(A) Homologous human regions of the mouse VPE and PSE are bound by EOMES and mediators of the Nodal signaling pathway in hESCs and hDE. 1=(Brown et al., 2011) 2=(Kim et al., 2011), 3=(Teo et al., 2011). ChIP-seq data showing regions bound by SMAD2/3 (purple), SMAD4 (green), FOXH1 (orange) and EOMES (red) are represented by coloured bars and were aligned to the EOMES locus on the UCSC Genome browser Human Mar. 2006 (NCBI36/hg18) Assembly (http://genome.ucsc.edu/). Homologous regions to the mouse VPE and PSE are highlighted in grey. Human VPE, PSE_a and PSE_b (hVPE, hPSE_a, hPSE_b). FoxH1 binds the conserved FoxH1 binding site at the VPE in hDE.
Figure S7: Definitive endoderm differentiation

(A) Schematic of protocol to differentiate ESC to definitive endoderm (DE) fate. ESC were grown in the absence of LIF for 2 days to form embryoid bodies (EB) and then differentiated in N2B27 medium, 20ng/ml ActivinA and 20ng/ml EGF for a further 3 days. (B) qPCR of Eomes mRNA demonstrates a dramatic increase in expression over the course of the 5 day differentiation regime. Gene expression is normalised to Gapdh. (C) 2D confocal images of d5 DE EBs stained with antibodies against definitive endoderm markers Eomes, Lhx1 or Foxa2, and counterstained with DAPI.
Figure S8: NG Capture-C from the *Eomes* enhancers.

(A) NG Capture-C interaction profiles of the PSE_a, PSE_b, and VPE from ESC (blue) and DE (green). Tracks show mean interactions of normalized biological replicates (n=3), subtraction of ESC from DE (Subtr.) and DESeq2 significant differences between DE and ESC (-log(P_adj); p≤0.05). Open chromatin was determined by ATAC-seq in both ESC and DE, ChIP-seq of the boundary element CTCF in ESC is from published data (Handoko et al., 2011) and H3K4me3 ChIP-seq was generated in triplicate from DE. FourCSeq comparison of NG Capture-C between DE and ESC from the PSE_a (B), PSE_b (C), and VPE (D). Red circles mark fragments with more interactions than expected based upon proximity to the promoter (green line), Blue Diamonds show fragments with significantly different interactions between the two conditions (P≤0.05), Orange Diamonds show fragments with enriched reactions that are significantly different between the two conditions.
Figure S9: NG Capture-C from the *Eomes* promoter.

(A) NG Capture-C interaction profiles of the *Eomes* promoter from terminally differentiated erythrocytes (Ery, grey), ESC (blue) and DE (green). Tracks show mean interactions of normalized biological replicates (n=3), subtraction of ESC and PHS from DE (Subtr.) and DESeq2 significant differences between the cell types (-\log(P_{adj}) ; p \leq 0.05). Open chromatin was determined by ATAC-seq in all three cell types (n=3), ChIP-seq of the boundary element CTCF in ESC is from published data (Handoko et al., 2011) and H3K4me3 ChIP-seq was generated in triplicate from DE.

(B) FourCSeq comparison of NG Capture-C of the *Eomes* promoter between DE, ESC and Ery. Comparison condition is shown in subscript. Red circles mark fragments with more interactions than expected based upon proximity to the promoter (green line), Blue Diamonds show fragments with significantly different interactions between the two conditions (P \leq 0.05), Orange Diamonds show fragments with enriched reactions that are significantly different between the two conditions. (C) Comparison of MACS2 peak call for ATAC-seq from DE and ESC.
Figure S10: Long-range NG Capture-C from the Eomes promoter.

NG Capture-C interaction profiles of the Eomes promoter (chr9:116890604-120321539) from erythrocytes (grey), ESC (blue) and DE (green). Tracks show mean interactions of normalized biological replicates (n=3), subtraction of ESC from DE (Subtr.) and DESeq2 significant differences between DE and ESC (-log(Padj); p≤0.05). Location of the Polycomb Repressor Complexes components (Ezh2, Suz12, Ring1b) and associated histone modification (H3K27me3) in ESC are shown (Ku et al., 2008; Mikkelsen et al., 2007). Open chromatin was determined by ATAC-seq in all three cell types (n=3), ChIP-seq of the boundary element CTCF in ESC is from published data (Handoko et al., 2011) and H3K4me3 ChIP-seq was generated in triplicate from DE.
Figure S11: Mapping enhancers within the Eomes compartment.

ChIP-seq of histone modifications H3K4me1 (light blue), H3K27me3 (red) and H3K27ac (light green) in ESC, epiblast like cells (EpiLC) and mesoderm (MES) (Alexander et al., 2015; Buecker et al., 2014; Consortium, 2012). Open chromatin was generated using ATAC-seq in ESC and DE (n=3). ChIP-seq of TFs involved in endoderm and anterior mesendoderm specification. Smad2/3 and Tcf3 in ESC (blue) and DE (green) (Wang et al., 2017). Otx2 in EpiLC (Buecker et al., 2014), Lhx1 in P19 mesendoderm (ME) (Costello et al., 2015), and Brachyury (T) (Lolas et al., 2014) in MES. Regions of increased chromatin accessibility unique to ESC (-73kb) and those associated with Smad2/3 occupancy uniquely in DE (-93kb, -45kb, -38kb, PSE_a, VPE and +9kb) are highlighted as in Fig. 5B. In addition, a TF binding hotspot accessible in both ESC and DE (-88kb), and the PSE_b, are also highlighted.
Table S1: Primers used in this study

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeting vectors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VPE Recombineering</td>
<td>GGCTGGGGTTGGG</td>
<td>GGTCGCCAAAAAAGTTT</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td>GAAGGAGTGTATTTC</td>
<td>GAGGACGGGGAGAAGA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCTGGAGATGCAAAG</td>
<td>CTTGTCAGCAGCTCAC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATTTGTCCTCCGATTC</td>
<td>GTATATCGAAGTTAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAATTAAACCTCAC</td>
<td>AAGCTTGAAGTTAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TAAAGGGC</td>
<td>AAGCTTGAAGTTAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSE AatII</td>
<td>TGACGTCTCTGTTC</td>
<td>ACCAGAGACGTATG</td>
<td>2.7kb</td>
</tr>
<tr>
<td></td>
<td>AAAAAGCACTACGGG</td>
<td>TTTCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Transgenic reporter</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VPE LacZ</td>
<td>GCCCTGGGAGATGC</td>
<td>CAGCTCAGGTATTC</td>
<td>696bp</td>
</tr>
<tr>
<td></td>
<td>AAGATTG</td>
<td>TTCTGGC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Genotyping</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VPE WT</td>
<td>TCGTTGAGTGTTGA</td>
<td>AGCGAGGACATCCA</td>
<td>369bp</td>
</tr>
<tr>
<td></td>
<td>GCAGGGAG</td>
<td>CGGAAAAC</td>
<td></td>
</tr>
<tr>
<td>VPE Δ</td>
<td>TCGTTGAGTGTTGA</td>
<td>TTTGGAGGACGGGA</td>
<td>264bp</td>
</tr>
<tr>
<td></td>
<td>GCAGGGAG</td>
<td>AAGACTG</td>
<td></td>
</tr>
<tr>
<td>PSE WT</td>
<td>AGGTTGGCTCTTATA</td>
<td>GCATTGAGTTGAAG</td>
<td>328bp</td>
</tr>
<tr>
<td></td>
<td>CAGGGT</td>
<td>GTGGG</td>
<td></td>
</tr>
<tr>
<td>PSE Δ</td>
<td>AGGTTGGCTCTTATA</td>
<td>TCACAAGTCTCTCC</td>
<td>246bp</td>
</tr>
<tr>
<td></td>
<td>CAGGGT</td>
<td>GCCAC</td>
<td></td>
</tr>
<tr>
<td>PSE_b WT</td>
<td>TTGCGTTTGTGGG</td>
<td>CCATCAGTGAGA</td>
<td>427bp</td>
</tr>
<tr>
<td></td>
<td>TTTGGG</td>
<td>GTAGGC</td>
<td></td>
</tr>
<tr>
<td>PSE_b Δ</td>
<td>GGCTATTGCCTCCA</td>
<td>CCATCAGTGAGA</td>
<td>712bp</td>
</tr>
<tr>
<td></td>
<td>TACAGC</td>
<td>GTAGGC</td>
<td></td>
</tr>
<tr>
<td>LacZ</td>
<td>TTACCAGGGCGAAG</td>
<td>GCGGCAGTAAGGCAG</td>
<td>300bp</td>
</tr>
<tr>
<td></td>
<td>CAGCGTGTGGG</td>
<td>GTCGGGGATAGT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RT-PCR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gapdh</td>
<td>CAATGACCCCTTCA</td>
<td>GATTCGCTCCTGGGA</td>
<td>145bp</td>
</tr>
<tr>
<td></td>
<td>TTGACC</td>
<td>AGATG</td>
<td></td>
</tr>
<tr>
<td>Eomes</td>
<td>TGTTTTCTGGAAG</td>
<td>AGGTCTGAGTTTGG</td>
<td>323bp</td>
</tr>
<tr>
<td></td>
<td>TGGTTCTGGC</td>
<td>AAGTTTCCATTCC</td>
<td></td>
</tr>
</tbody>
</table>
Table S2: Antibodies used in this study

<table>
<thead>
<tr>
<th>Name</th>
<th>Catalog number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foxa2</td>
<td>sc-6554</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Lhx1</td>
<td>sc-19341</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>TBR2/Eomes</td>
<td>ab23345</td>
<td>Abcam</td>
</tr>
<tr>
<td>GFP AlexaFluor 488</td>
<td>A21311</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>Goat IgG AlexaFluor 594</td>
<td>A11058</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>Rabbit IgG AlexaFluor 488</td>
<td>A21206</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>Anti-H3K4me3</td>
<td>07-473</td>
<td>Millipore</td>
</tr>
</tbody>
</table>

Table S3. Long-range Foxa2 and Lhx1 promoter interactions identified by NG Capture-C

Click here to Download Table S3

Table S4. Probes used for NG Capture-C.

Click here to Download Table S4

Table S5. Accession codes used in this study.

Click here to Download Table S5